Eisai Inc. Announces Appointment Of Senior Vice President And General Counsel, Allen Waxman

WOODCLIFF LAKE, N.J., April 30, 2012 /PRNewswire/ -- Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Allen Waxman to the position of Senior Vice President and General Counsel.  In this position, Mr. Waxman will lead the Office of the General Counsel, where he will be responsible for all legal matters for the company in the U.S.  Mr. Waxman will be a member of the company's Executive Committee and will also join others in providing leadership for a number of global legal matters for Eisai. 

(Photo:  http://photos.prnewswire.com/prnh/20120430/NY96382 )

(Logo:  http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) 

Mr. Waxman joins Eisai from Kaye Scholer, LLP, where he was a partner and chair of the firm's Life Sciences Group. Prior to Kaye Scholer, he held the position of General Counsel at Pfizer, where he had global responsibility for leading the Legal Division and served as a member of the company's Executive Leadership Team.

Earlier in his career, Mr. Waxman was a partner at Williams & Connolly, LLP, based in Washington D.C., where he tried civil and criminal cases, and served as national counsel in pharmaceutical litigation.

"We are very pleased to welcome Allen to Eisai," said Lonnel Coats, President and CEO of Eisai Inc.  "Allen's expertise and leadership will help us continue driving sound, ethical and legally compliant business practices here at Eisai, contributing to our company's human health care mission to help improve the lives of patients and their families."

Mr. Waxman is currently Chairman of the Board of Equal Justice Works, a national not-for-profit dedicated to mobilizing the next generation of lawyers working in the public interest; serves as a Member of the Regional Board, Anti-Defamation League, New York Lawyers' Division; serves as a Member of the Leadership Council of Day One -- an organization dedicated to working with youth to end dating violence; and acts as an Advisory Board Member to the BNA Pharmaceutical Law and Industry Report.  Previously, Mr. Waxman was Vice-Chairman of the Legal Section Executive Committee for PhRMA, an adjunct professor at Georgetown University Law Center, and the Chairman of the Board of the Thurgood Marshall Academy Public Charter High School in Washington, D.C.

Mr. Waxman holds a Bachelor of Arts degree, magna cum laude, from Dartmouth College and a Juris Doctor, magna cum laude, from Harvard Law School. Upon graduating from law school, he clerked for the Honorable Thomas Penfield Jackson of the United States District Court for the District of Columbia.

Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. 

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

SOURCE Eisai Inc.